End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
1,027 INR | +1.05% | -5.14% | -35.88% |
03/05 | Transcript : Tatva Chintan Pharma Chem Limited, Q4 2024 Earnings Call, May 03, 2024 | |
03/05 | Tatva Chintan Pharma Chem Limited Recommends Final Dividend for the Financial Year 2023-2024 | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The company's profit outlook over the next few years is a strong asset.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 71.16 times its estimated earnings per share for the ongoing year.
- The company appears highly valued given the size of its balance sheet.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Specialty Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-35.88% | 285M | C- | ||
+20.59% | 68.69B | A- | ||
-1.02% | 49.19B | A- | ||
+23.82% | 44.73B | B+ | ||
+30.26% | 28.24B | A- | ||
+7.56% | 19.22B | C+ | ||
+10.55% | 16.68B | B+ | ||
-5.73% | 16.08B | B+ | ||
-21.45% | 15.62B | A- | ||
-20.45% | 13.89B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- TATVA Stock
- Ratings Tatva Chintan Pharma Chem Limited